Limited contribution of CYP3A5 to the hepatic 6β-hydroxylation of testosterone

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 370, Issue 1, 2004, Pages 71-77

  Kamdem, Landry K ^a   Meineke, Ingolf ^a   Koch, Ina ^b   Zanger, Ulrich M ^c   Brockmöller, Jürgen ^a   Wojnowski, Leszek ^d  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Epidauros Biotechnologie AG   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

CYP3A4; CYP3A5; Polymorphism; Testosterone hepatic metabolism

Indexed keywords

6BETA HYDROXYTESTOSTERONE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CATALYST; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER METABOLISM; LIVER MICROSOME; PROTEIN EXPRESSION; TESTOSTERONE METABOLISM;

BACULOVIRIDAE; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GERMANY; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; POLYMORPHISM, GENETIC; RNA, MESSENGER; TESTOSTERONE;

EID: 4344673341     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Backman JT, Kivisto KT et al (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53-58
2. Chang TK, Chen J et al (2003) Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol Sci 71:11-19
3. De Waziers I, Cugnenc PH et al (1990) Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394
4. Evert B, Eichelbaum M et al (1997) Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells. Naunyn-Schmiedebergs Arch Pharmacol 355:309-318
5. Gelboin HV, Krausz KW et al (1995) Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol 50:1841-1850
6. Gillam EM, Guo Z et al (1995) Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 317:374-384
7. Goh BC, Lee SC et al (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690
8. Gorski JC, Hall SD et al (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653
9. Hustert E, Haberl M et al (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779
10. Kinirons MT, O'Shea D et al (1993) Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 54:621-629
11. Kinirons MT, Krivoruk Y et al (1999) Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio. Br J Clin Pharmacol 47:223-225
12. Koch I, Weil R et al (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114
13. Kuehl P, Zhang J et al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391
14. Nishimura M, Yaguti H et al (2003) Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123:369-375
15. Ozdemir V, Kalowa W et al (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388
16. Paine MF, Khalighi M et al (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562
17. Santos A, Zanetta S et al (2000) Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6:2012-2020
18. Shih PS, Huang JD (2002) Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 30:1491-1496
19. Shimada T, Yamazaki H et al (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423
20. Wang H, Dick R et al (1998) Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry 37:12536-12545
21. Westlind-Johnsson A, Malmebo S et al (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761
22. Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475-490
23. Williams JA, Ring BJ et al (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891
24. Wolbold R, Klein K et al (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988
25. Wrighton SA, Brian WR et al (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207-213
26. Yuan R, Madani S et al (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319